Opportunity Summary:
The Health Resources and Services Administration (HRSA) is accepting applications for fiscal year (FY) 2021 for the Sickle Cell Disease Treatment Demonstration Program (TDP). The purpose of the TDP is to increase access to quality, coordinated, comprehensive care for individuals with sickle cell disease by: 1) increasing the number of clinicians or health professionals knowledgeable about the care of SCD, 2) improving the quality of care provided to individuals with sickle cell disease, and 3) improving care coordination with other providers.

HRSA funds a portfolio of three coordinated programs to improve outcomes of individuals with SCD and their families: the Sickle Cell Disease Newborn Screening Follow-up Program (HRSA-21-036), the Sickle Cell Disease Treatment Demonstration Program (HRSA-21-032), and the Hemoglobinopathies National Coordinating Center (funded by a contract). Together the programs strengthen the sickle cell disease system of care and support by: 1) educating patients, families and clinicians to improve knowledge and capacities; 2) linking individuals and families to evidence-based care; and 3) fostering partnerships between clinicians, community organizations and other stakeholders to improve the ability to deliver coordinated, comprehensive care across the lifespan.

The goal of the TDP is to improve outcomes of individuals with SCD and their families by developing and supporting a regional SCD infrastructure that includes components necessary for providing comprehensive services to individuals with SCD and their families. The successful recipient must collaborate with clinics/practices in at least seven (7) states within a single region in order to: develop and support comprehensive SCD care teams 1; implementation of telehealth technologies for health care delivery, education and health information services 2; increased access to evidence-based care and the latest treatment options; and increased collaboration and care coordination within each region.

There will be a technical assistance webinar on Friday, March 19, 2021 from 2 – 3 pm ET.

Eligibility & Requirements:
- A federally qualified health center, a nonprofit hospital or clinic, or a university health center that provides primary health care, that has a collaborative agreement with a community-based sickle cell disease organization or a nonprofit entity with experience in working with individuals who have sickle cell disease; and has at least 5 years of experience in working with individuals who have sickle cell disease.

Internal Nomination Process:
Interested applicants should submit the following documents:

1. JHU Limited Submission Cover Sheet
2. Proposal (maximum of two pages of text only, single spaced: 12-pt font and one-inch margins) (Note: figures, tables, and other reference material may be included in addition to the 2 pg. text limit)
3. Curriculum Vitae of investigator, including current external research support and publications
4. Budget (two pages maximum)

Click Here to Apply

Questions? Comments? Email the Research Development Team at resapp@jhu.edu.